VivoSeq
Neurology

Multiple System Atrophy

40

Pipeline Programs↗

21

Active Trials↗

25

Companies Involved↗

Multiple System Atrophy is a moderately active landscape with 40 programs across 25 companies. The most active players are iRegene Therapeutics Co., Ltd., Ionis Pharmaceuticals, Johnson & Johnson. 4 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

27/100

Mech. Concentration

10/100

Completion Rate

76/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

iRegene Therapeutics Co., Ltd.

1 program

Phase 1Ionis Pharmaceuticals logo

Ionis Pharmaceuticals

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 1Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 1Teva logo

Teva

2 programs

Phase 2Y

Yoda Therapeutics Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical3

Levodopa

Merz Pharmaceuticals GmbH

BHV3241, Verdiperstat

Biohaven Pharmaceuticals, Inc.

Levodopa Test

University Hospital, Toulouse

Phase 19

Domperidone

Johnson & Johnson

Fludrocortisone

Alnylam Pharmaceuticals

Human Dopaminergic Progenitor Cells

iRegene Therapeutics Co., Ltd.

CS10BR05

Corestemchemon, Inc.

Aleeto

Beijing Tiantan Hospital

Phase 218

Lithium Carbonate

Solvay Pharmaceuticals

Fluoxetine

Vitae Pharmaceuticals Inc., an Allergan affiliate

Exenatide

AstraZeneca

Sirolimus

Prism Pharmaceuticals

YA-101

Yoda Therapeutics Inc.

Phase 36

Rifampicin

Boehringer Ingelheim

Ampreloxetine

Theravance Biopharma

Tllsh2910

National Taiwan University Hospital

Verdiperstat

Biohaven Pharmaceuticals, Inc.

Amlenetug

Lundbeck

Approved4

Droxidopa

Lundbeck

Riluzole

Azurity Pharmaceuticals

Pseudoephedrine

Kenvue Brands

Rifampin

Sanofi

Analysis

Modality Breakdown

82%

Small molecule

36 of 44 classified programs — the dominant modality here.

18%ALL OTHERSCell therapy49%Monoclonal antibody25%Peptide12%Gene therapy12%

Small molecule leads; the ring shows all 44 classified programs, each share of the total. Modality classified for 100% of 49 pipeline programs.

Analysis

Trial Status

45

clinical trials

Completed16 · 36%
Recruiting10 · 22%
Active, not recruiting8 · 18%
Terminated5 · 11%
Not yet recruiting3 · 7%
No longer available1 · 2%
Other2 · 4%

Clinical Trials

Trial Activity

45 trials

A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
Recruiting·YYoda Therapeutics Inc.·Phase 2·NCT06848231·75 enrolled
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
Recruiting·Teva logoTeva·Phase 2·NCT06568237·350 enrolled
Insulin Resistance in Multiple System Atrophy
Recruiting·UUniversity Hospital, Bordeaux·N/A·NCT04250493·124 enrolled
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)
Recruiting·Ionis Pharmaceuticals logoIonis Pharmaceuticals·Phase 1·NCT04165486·40 enrolled
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
Recruiting·TTiziana Life Sciences LTD·Phase 2·NCT06868628·5 enrolled
MSA-01 in Multiple System Atrophy
Recruiting·TTokyo University·Phase 3·NCT07446894·140 enrolled
The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy
Recruiting·—·Phase 1·NCT06765733·20 enrolled
Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.
Recruiting·—·Phase 1/2·NCT06831500·36 enrolled
High-Altitude Neurodegeneration Cohort (HANC) Phase II: A Prospective Multicenter Validation Study on the Association Between Chronic Physiological Hypoxia and Multiple System Atrophy
Recruiting·WWest China Hospital·N/A·NCT07657520·20,000 enrolled
An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy
Recruiting·Teva logoTeva·Phase 2·NCT07197866·200 enrolled
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy
Active, not recruiting·MMayo Clinic·Phase 2·NCT05167721·71 enrolled
GDNF Gene Therapy for Multiple System Atrophy
Active, not recruiting·BBrain Neurotherapy Bio, Inc.·Phase 1·NCT04680065·9 enrolled
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
Active, not recruiting·TTheravance Biopharma·Phase 3·NCT05696717·102 enrolled
A Study of Lu AF82422 in Participants With Multiple System Atrophy
Active, not recruiting·Lundbeck logoLundbeck·Phase 2·NCT05104476·64 enrolled
Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)
Active, not recruiting·CCytora Ltd.·Phase 1·NCT05698017·10 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)